Kornimate/medical-research-clean huggingface dataset:
clinical trial to assess the effects of low-fat dairy on systolic blood pressure

Conditions: Hypertension

Summary: the purpose of this study is to determine if increased consumption of low-fat dairy can reduce blood pressure and improve endothelial function in men and women with pre or stage-1 hypertension.


Eligibility criteria:
inclusion criteria: * subject is a female or male, 20-69 years of age, inclusive. * subject has a bmi of 18.5 to 39.9 kg/m2, inclusive. * subject has resting blood pressure measurements meeting the criteria for pre-hypertension (sbp = 120 to 139 mm hg and/or dbp = 80 to 89 mm hg) or stage 1 hypertension (sbp = 140 to 159 mm hg or dbp = 90 to 99 mm hg) * subject reports history of consuming, on average, ≤2 servings/d of dairy foods as part of their normal diet * subject is willing to consume ≤1 serving/d of dairy foods (other than the study products provided) during each treatment phase. * subject is willing to maintain a stable body weight and habitual diet and physical activity patterns throughout the trial, with the exception of specific study instructions related to study product intake, alcohol intake, and physical activity. exclusion criteria: * subject has known coronary heart disease (chd) or a chd risk equivalent * subject has a history of any major trauma or major surgical event * subject has digital deformities that would prevent endopat measurements. * subject has used medications known to alter body weight * subject has used medications or dietary supplements that, in the opinion of the investigator, have strong potential to influence blood pressure or endothelial function * subject has extreme dietary habits (e.g., atkins diet, very high protein/low carbohydrate).
effects of transcranial magnetic stimulation (tms) and cognitive training for alzheimer patients

Conditions: Alzheimer Disease, Early Onset

Summary: current diagnosis of alzheimer disease is made by clinical, neuropsychological, and neuroimaging assessments. routine structural neuroimaging evaluation is based on nonspecific features, such as atrophy, which is a late feature in the progression of the disease. therefore, developing new approaches for early and specific recognition of alzheimer disease at the prodromal stages is of crucial importance. in the present study the investigators would like to examine if combined treatment with tms and cognitive training (cotra) for several weeks can produce a sustained improvement in cognitive and behavioral symptomatology of alzheimer's disease (ad) patients. a number of in vivo neuroimaging techniques, which can be used to reliably and noninvasively assess aspects of neuroanatomy, chemistry, physiology, and pathology, hold promise.


Eligibility criteria:
inclusion criteria: * male or female age 55-85 years * patients diagnosed with early or moderate stage of alzheimer's disease, according to the dsm-iv criteria. * mmse score 15 to 26 * global dementia rating 1 or 2 * physically acceptable for the study as confirmed by medical history and exam, clinical laboratory results and ekg * spouse, family member or professional caregiver agree and capable of taking care and responsibility for the participation of the patient in the study (transportation for the patient to and from the investigator's clinic, answering questions regarding the patient's condition and assuming responsibility for medication) * written informed consent by patient or legally responsible caregiver. * able to undergo mri scanning sessions (e.g., prior to the onset of the study, upon the attainment of the primary end-point and at the end of the study). * commitment to participation in six-to eighteen weeks of the trial regimen consisting of approximately1 hour tms stimulation and cognitive training daily treatment of five days a week - six to eighteen weeks (and up to two treatments a day in case the third tms stimulation and cognitive training treatment protocol if necessary). exclusion criteria: * severe agitation; * mental retardation; * unstable medical condition; * use of benzodiazepines or other hypnotics during the study and preceding two weeks; * pharmacological immunosuppression; * participation in a clinical trial with any investigational agent within two weeks prior to study enrollment; * alcoholism; * history of epileptic seizures or epilepsy; * contraindication for performing mri scanning; * clinically significant abnormal laboratory findings which have not been approved by the project director;

Keywords: alzheimer tms cognitive training
pilot of lifestyle behavior intervention for non-alcoholic fatty liver disease

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: the purpose of this study is to pilot test a behavioral lifestyle intervention for hispanic/latino patients with non-alcoholic fatty liver disease (nafld)


Eligibility criteria:
inclusion criteria: * self-reported hispanic/latino * have been diagnosed with nafld * able to speak english or spanish * have access to internet, either on their phone, at home or at some other location convenient to the participant exclusion criteria: * does not have a working telephone number
erb:yag laser versus pelvic floor training for the treatment of women with mild to moderate stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: this is a pilot study to assess the feasibility and safety to run a randomized controlled trial that compared the effectivity of erbium:yag vaginal laser versus pelvic floor training in women with mild to moderate stress urinary incontinence.

this pilot study attempts to demonstrated the feasibility and security to run a randomized controlled study that compared the effectivity of erbium:yag laser used vaginally versus pelvic floor training, coached by a physiotherapist expert in pelvic floor disorders. patients are going to be randomized to pelvic floor exercises (10 sessions) or erbium:yag laser (2 sessions), and assess the results at 6 and 12 moths later on.

Eligibility criteria:
inclusion criteria: * mild to moderated stress urinary incontinence exclusion criteria: * mixed urinary incontinence * pelvic organ prolase greater than stage 2 * previous surgery for stress urinary incontinence and/or pelvic organ prolapse * severe stress urinary incontinence
natural history study for achromatopsia

Conditions: Achromatopsia

Summary: in preparation for human clinical trials we intend to undertake a detailed phenotypic study to help to identify patients who may be suitable for therapeutic intervention. in addition, with the recent availability of advanced imaging modalities, further detailed phenotypic investigations will also be valuable in helping to probe the relationship between structure and function and may shed light on disease mechanisms.


Eligibility criteria:
inclusion criteria: * patients with molecularly proven achromatopsia or a typical clinical achromatopsia phenotype with genetic screening pending. * minimum subject age of 3 years. * able to give consent/parent or guardian able to give consent. exclusion criteria: * patients unable or unwilling to undertake consent or clinical testing. * patients unwilling to donate a blood sample in order to establish the genetic cause of their condition.

Keywords: achromatopsia cngb3 cnga3
determinants of the level of anti-sars-cov-2 igg antibodies after vaccination study

Conditions: SARS-CoV2 Infection; SARS-CoV2 Antibodies

Summary: great expectations to control the pandemic are placed in vaccines against covid-19. currently, the four covid-19 vaccines approved in the european union. we have designed the study assessing the anti-sars-cov-2 igg antibody titer after vaccination cycle the bnt162b2 vaccine in several time points relating these results to the covid-19 history and severity of symptoms during the disease and after the first and second vaccine dose

the study includes healthy, unselected volunteers from the staff of antoni jurasz university hospital no.1 in bydgoszcz and students of collegium medicum, nicolaus copernicus university. to meet the inclusion criteria patients will have to be vaccinated with two doses of the bnt162b2 vaccine. the assessment of the anti-sars-cov-2 igg antibody titer at several time points in each participant. fresh serum samples were used to measure sars-cov-2 igg on the siemens atellica system (siemens healthineers, erlangen, germany). results of sars-cov-2 igg were given as u/ml, whereby the cut-off for positivity was defined as ≥1.0 u/ml.

Eligibility criteria:
inclusion criteria: * provision of informed consent to study * age ≥ 18 years * receiving two doses of the bnt162b2 vaccine exclusion criteria: * patients who did not complete 2-dose vaccination schedule * patients who received any other vaccine than bnt162b2 * patients considered by investigator to be unable to cooperate
effect of quadratus lumborum block with compound lidocaine and esketamine on pain after colorectal surgery

Conditions: Postoperative Pain

Summary: purpose: to explore effects of ultrasound-guided quadratus lumborum block with compound lidocaine and esketamine on postoperative pain after colorectal surgery.

poor post-surgical pain control is a leading factor that hinders the physicalrehabilitation, and causes acute cognitive impairment and chronic painsyndrome. recently, the multimodal analgesia strategies to minimise opioidrelated side effects are highly desirable in open surgical procedures. quadratus lumborum block is a novel technique. although ropivacaine is most commonly used forthis technique, the analgesic duration remains not dissatisfied. compared with ropivacaine, compound lidocaine injection has a better and longer analgesic activity since it contains menthol and ethanol with appropriate concentrations. however, whether compound lidocaine injection is efficiency in the quadratus lumborum block for abdominal surgery lacks investigations. herein, we will evaluate the efficacy of ultrasound-guided quadratus lumborum block (usg-qlb) with compound lidocaine injection and esketamine for postoperative analgesia in patients undergoing colorectal surgery.

Eligibility criteria:
inclusion criteria: 1. subject is scheduled to undergo colorectal cancer surgery under general anesthesia 2. subject's american society of anesthesiologists physical status is i-iii. 3. the subject's parent/legally authorized guardian has given written informed consent to participate exclusion criteria: 1. subject has a diagnosis of bronchial asthma, coronary heart disease, severe hypertension, renal failure or liver failure. 2. subject has a diagnosis of insulin dependent diabetes. 3. subject is allergy and contraindication to local anesthetics or any components of local anesthetics. 4. subject has a history of chronic pain, a history of alcohol or opioid abuse, pre- existing therapy with opioids, intake of any analgesic drug within 48 hours before surgery. 5. subject has any contraindication for the use of patient-controlled analgesia (pca). 6. subject is pregnant or breast-feeding. 7. subject is obese (body mass index \>30kg/m\^2). 8. subject is incapacity to comprehend pain assessment and cognitive assessment.

Keywords: compound lidocaine esketamine quadratus lumborum block opioid consumption
evaluation of latent pulmonary arterial hypertension in congenital shunt lesions

Conditions: Atrial Septal Defects; Ventricular Septal Defects

Summary: prospective, monocentric study for the evaluation of latent pulmonary arterial hypertension in patients with congenital shunt lesions lost to follow-up. lost to follow-up is defined as latest clinical control ≥ 5 years.

pulmonary arterial hypertension (pah) in patients with congenital heart disease (chd) usually develops secondary to chronic volume overload of the pulmonary circulation following left to right shunt. this overload leads to elevated pulmonary artery pressure (pap) and later to increased pulmonary vascular resistance (pvr). this causes pressure overload in the right heart, and thereby right ventricular (rv) and right atrial (ra) dysfunction, which may implicate considerable morbidity and even mortality. since pah nowadays is mostly detected when symptoms occur and pap are elevated, the disease already evolved to an advanced (partially irreversible) stage and treatment is often initiated too late. dismissal from follow-up after a surgical correction of simple chd was customized in the seventies and eighties. there is no literature available that learns us whether these patients really need follow-up or not. a substantial number must have insidiously developed pah or mild pulmonary vascular disease (pvd) and still are prone to develop pah later in life. it is relevant to recall these patients dismissed from follow-up in the past, because they might carry a lot of useful information on the natural history of pah development. focus will lie mainly on patients with simple shunt lesions, as atrial septal defect (asd) and ventricular septal defect (vsd).

Eligibility criteria:
inclusion criteria: * previous repair for secundum asd, vsd exclusion criteria: * other congenital heart disease * chronic lung disease or total lung capacity \< 80% of predicted value * history of pulmonary embolism
adx10059 as an add-on therapy to proton pump inhibitors (ppis) in patients with gastroesophageal reflux (gerd)

Conditions: Gastroesophageal Reflux

Summary: the purpose of this study is to evaluate the effect of adx10059 in patients with gastroesophageal reflux disease who are partial responders to proton pump inhibitors


Eligibility criteria:
inclusion criteria: * diagnosis of typical gerd * partial responder to a stable standard clinical symptoms control dose of ppi therapy * body mass index ≤ 32 kg/m2 exclusion criteria: * exclusively atypical symptoms of gerd * symptoms that have been shown not to be associated with gerd * erosive oesophagitis * treated with a dose of ppi greater than the dose indicated for clinical symptom control of gerd * hiatus hernia \> 3 cm * current diagnosis of co-existing psychiatric disease * known clinical significant allergy or known hypersensitivity to drugs * is pregnant or breast-feeding * has received sodium valproate or topiramate within 30 days of screening * has a history of a significant medical condition that may affect the safety of the patient or preclude adequate participation in the study

Keywords: gastroesophageal reflux proton pump inhibitor heartburn regurgitation
esophageal impedance and manometry measurements and dysphagia symptom scoring

Conditions: Dysphagia, Esophageal

Summary: comparison of manometry measurements and endoflip balloon measurements in patients with dysphagia and a known esophageal diagnosis

gastrointestinal (gi) motility problems are very common in the general population. dysphagia, difficulty swallowing, is one of the most common issues in gastroenterology. in many patients, esophageal obstruction is not identified despite workup with upper endoscopy or barium swallow x-ray. patients are often referred to the motility laboratory for evaluation of non-obstructive dysphagia. transnasal esophageal manometry-impedance is a diagnostic test to measure the pressures and coordination of the esophagus during swallowing. the endolumenal functional lumen imaging probe (endoflip) is another instrument used to measure the lumen distensibility of the esophagus and pylorus. both tests are fda-approved and are currently being used in clinical practice. however, correlation of the results obtained from these tests with clinical syndromes and symptoms is not clearly understood. furthermore, the relationship between esophageal impedance-manometry and endoflip results has never been defined. the primary aim is to develop a registry of patients undergoing esophageal manometry-impedance and endoflip from the gi motility lab at the iu university hospital

Eligibility criteria:
inclusion criteria: * all patients who presented to gi motility lab at iu university hospital for esophageal manometry-impedance and/or endoflip exclusion criteria: * age \<18 yrs old * unable to communicate verbally with the staff
heating precondition of streamlined liner of the pharynx airway decrease the incidence of sore throat

Conditions: Complication of Artificial Airway

Summary: the effect of heating precondition of streamlined liner of the pharynx airway (slipa) on respiratory mechanics and sore throat was investigated.


Eligibility criteria:
inclusion criteria: * hysteroscopic surgery * general anesthesia exclusion criteria: * upper respiratory disease * communication disfunction
filter lifespan in continuous renal replacement therapy

Conditions: Critically Ill; Continuous Renal Replacement Therapy; Infections

Summary: the only supportive therapy for patients with aki is renal replacement therapy (rrt). in the icu setting, continuous rrt (crrt) is mostly favored. in a post-hoc analysis of the rich trial (regional citrate versus systemic heparin anticoagulation for crrt in critically ill patient with aki), it was shown that the filter life span is associated with an increased rate of new infection and that the type of anticoagulants did not directly affect infection rate. the mechanisms of this infection rate is unknown.

approximately every second patient in the icu suffers from acute kidney injury (aki) which complicates the clinical course of these patients. continuous renal replacement therapy (crrt) has become the most widely used form of renal support in critically ill patients as it allows continuous, controlled removal of fluids and is hemodynamically better tolerated compared to intermittent dialysis. the requirement for intravascular access and artificial circuits may increase the risk of infection. however, there are no studies analyzing the incidence and characteristics of infections in critically ill patients with crrt or the implications for outcome. therefore, this observational trial investigates the factors that influences new onset infection in critically ill patients with crrt.

Eligibility criteria:
inclusion criteria: * adult patients (age ≥18 years) * critically ill patients with dialysis-dependent aki * continuous renal replacement therapy (crrt) * written informed consent exclusion criteria: * chronic kidney disease with estimated glomerular filtration rate (egfr)\<30ml/min/1.73m2 * chronic dialysis dependency * kidney transplant * (glomerulo-)nephritis, interstitial nephritis, vasculitis * patients on immunosuppression * patients with chronic inflammatory diseases (e.g. arthritis, hiv, chronic hepatitis) * persons with any kind of dependency on the investigator or employed by the sponsor or investigator
efficacy of recreational-therapeutic use of video games on the emotional state of stroke patients

Conditions: Stroke, Acute; Virtual Reality

Summary: according to the latest published literature reviews, stroke patients have a prevalence of 19.5% of minor depression and 21.7% of major depression. furthermore, the loss of autonomy is the most strongly correlated variable in these emotional disorders. in addition, emotional disturbances - in particular anxiety, sadness, crying, and anhedonia - are interpreted as natural reactions to the loss of physical capacity. along these lines, it has been shown that the use of virtual reality (vr) as a co-adjuvant therapy of neuro-rehabilitation in stroke patients with emotional disorders decreases the incidence of these disorders.

. primary objective - to evaluate the impact on mood, anxiety and depression in patients admitted to neurorehabilitation units after the use of non-immersive virtual reality with the nintento switch device in their rehabilitation treatment. secondary objectives * to describe the emotional state of patients before the use of non-immersive virtual therapy in their rehabilitation. * to describe the emotional state of patients after the use of virtual reality in their rehabilitation. * to compare the emotional state of patients before and after the implementation of virtual therapy in their rehabilitation. * to describe the emotional state of patients who have not used non-immersive virtual reality in their rehabilitation by choice. * to evaluate the efficacy of the involvement of the use of virtual reality therapy in patients with altered emotional state.

Eligibility criteria:
inclusion criteria: * to be of legal age * fluent in oral and written spanish. * patients with cognitive functions of expression and comprehension. exclusion criteria: * patients who are not undergoing neurorehabilitation treatment. * patients who have not yet started rehabilitation treatment.
dental tobacco control.net:improving practice

Conditions: Tobacco Use Disorder

Summary: this is a randomized, controlled trial (rct) to test the efficacy of an internet continuing dental education intervention designed to increase tobacco cessation counseling in dental practices. the intervention involves surveying practices regarding preventive care, surveying adult patients about their tobacco habits and preventive care provided by dental practice and training/educating the dentist and office staff on tobacco cessation. with patients who smoke and indicate that they have quit, we followed up with testing their saliva for the presence of cotinine. we have enrolled general dentists and periodontists who practice in the southeastern united states.

tobacco use has been described as the number one behavioral health problem of our time with a projected 8.4 million total smoking related deaths worldwide by the year 2020. current clinical practice guidelines entitled "treating tobacco use and dependence" provide a summary of evidence-based recommendations. despite the evidence of tobacco risk and the efficacy of tobacco control interventions, 30% of current smokers report that they have never been advised to stop smoking by a healthcare provider. nearly half (47.9%) of dentists report they have never intervened to assist tobacco users in quitting. our intervention is designed to improve the rate of tobacco cessation advice delivered in dental practices. this proposal is in response to the request for applications "translational research in dental practice-based tobacco control interventions" (rfa: de-03-007). our exploration of barriers and facilitators will assist in clarifying processes that influence translation of tobacco-related knowledge into clinical dental practice. our trial will integrate theoretically grounded methods of provider behavior change, medical informatics, and tobacco control research to translate guidelines into dental clinical practice. we will avoid a "one-size-fits-all" approach by tailoring strategies for tobacco cessation counseling to individual practices. the intervention will be longitudinal, with updates and continuous access for dentists and dental staff over 2 years. our evaluation will extend from processes of care to patient outcomes. ancillary analyses will assess differences in tobacco counseling rates associated with practice, provider, and patient-level variables including disparities in counseling by race. to assess the relative impact of various components of the multi-modal intervention, we will conduct secondary analyses of the association of amount of use of each specific component with frequency of tobacco cessation counseling within the intervention group.

Eligibility criteria:
inclusion criteria: * general dental practices that have internet access * periodontal practices that have internet access * patients of participating dental or periodontal practices exclusion criteria: * patients who were 18 years of age and younger

Keywords: tobacco control tobacco cessation tobacco use
the role of microbiota on the development of lung cancer

Conditions: NSCLC, Stage I; NSCLC, Stage II; NSCLC, Stage III; NSCLC Stage IV; Healthy Subjects

Summary: relationship between human microbiota and epidemiology of lung cancer

in this study,we aim to find some kinds of human microbiota , which were associated with development of non-small cell lung cancer.

Eligibility criteria:
inclusion criteria: * non-small cell lung cancer patients exclusion criteria: * long-term workers in the polluted environment, patients who had used antibiotics within 1 month before sampling,